Cumberland Pharmaceuticals Reports Q1 Revenue of $9.1 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CPIX?
Source: moomoo
Company Overview: Cumberland Pharmaceuticals is a pharmaceutical company focused on developing and marketing innovative products.
Financial Performance: The company reported a revenue of USD 9.1 million for the first quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CPIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CPIX
About CPIX
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, and Tacilia (omeprazole, amoxicillin and rifabutin) an oral capsule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cumberland Pharmaceuticals Q1 2026 Earnings Call Insights
- FDA Approval Expansion: Cumberland received FDA approval for expanded Caldolor labeling, now indicated for patients aged 3 months and older, which is expected to enhance market demand and strengthen product competitiveness.
- Strategic Transaction Progress: Cumberland has entered into an agreement with Apotex to sell its portfolio of marketed products for $100 million, which is anticipated to significantly reduce operating expenses and refocus the company on innovative product development.
- Financial Performance Overview: In Q1 2026, Cumberland's total revenue from FDA-approved brands was $9.1 million, while total operating expenses reached $12.3 million, resulting in a net loss of approximately $3.3 million, indicating challenges in profitability.
- Outlook Adjustment: Due to the impact of the strategic transaction, Cumberland is no longer targeting double-digit revenue growth for 2026, with management shifting focus towards cost reduction and advancing its product pipeline.
See More
CUMBERLAND PHARMACEUTICALS REPORTS Q1 ADJUSTED EPS OF USD -0.13
Company Overview: Cumberland Pharmaceuticals is a pharmaceutical company focused on developing and marketing innovative products for hospitals and specialty markets.
Financial Performance: The company reported a Q1 adjusted EPS of USD -0.13, indicating a loss during the quarter.
Market Position: Cumberland Pharmaceuticals aims to enhance its market presence through strategic partnerships and product development.
Future Outlook: The company is focused on expanding its product pipeline and improving financial performance in upcoming quarters.
See More
Cumberland Pharmaceuticals Reports Q1 Revenue of $9.1 Million
Company Overview: Cumberland Pharmaceuticals is a pharmaceutical company focused on developing and marketing innovative products.
Financial Performance: The company reported a revenue of USD 9.1 million for the first quarter.
See More
Cumberland Pharmaceuticals Strategic Transaction Unlocks $100 Million in Value
- Strategic Transaction Overview: Cumberland Pharmaceuticals has entered into a strategic transaction with Apotex, Canada’s largest pharmaceutical company, to acquire its portfolio of FDA-approved brands for $100 million in cash, aimed at unlocking value and sharpening focus on high-value product candidates.
- Financial Performance: In Q1 2026, Cumberland reported net revenues of $9.1 million, reflecting a 5% increase from Q1 2025, despite operating expenses reaching $12.3 million, resulting in a net loss of approximately $3.3 million, indicating challenges in expanding its product line.
- R&D Progress: Cumberland's ifetroban product has achieved breakthrough results in a Phase II clinical trial for patients with Duchenne muscular dystrophy, with the FDA granting Fast Track designation, which is expected to expedite its approval process and address unmet medical needs.
- Balance Sheet Status: As of March 31, 2026, Cumberland had total assets of $71 million, liabilities of $49.7 million, and shareholders' equity of $21.6 million, demonstrating financial stability and potential for future growth.
See More
Cumberland Pharmaceuticals Strategic Transaction Unlocks $100 Million in Value
- Strategic Transaction Announcement: Cumberland Pharmaceuticals has entered into a strategic transaction with Apotex, Canada's largest pharmaceutical company, to acquire its portfolio of FDA-approved brands for $100 million in cash, aimed at enhancing the company's focus on developing high-value product candidates to address unmet medical needs.
- Financial Performance Review: In the first quarter of 2026, Cumberland reported net revenues of $9.1 million, reflecting a 5% increase compared to the same period in 2025, indicating strong market performance following a year of double-digit growth in 2025, despite facing operating expenses totaling $12.3 million.
- R&D Pipeline Progress: Cumberland is developing ifetroban, a potent thromboxane antagonist for Duchenne muscular dystrophy, which has received Fast Track Designation from the FDA, potentially accelerating its clinical development and enhancing the company's competitive position in the biopharmaceutical sector.
- Balance Sheet Status: As of March 31, 2026, Cumberland's total assets stood at $71 million, with liabilities of $49.7 million and shareholders' equity of $21.6 million, demonstrating financial stability that supports future strategic investments and R&D initiatives.
See More
RedHill's RHB-204 Shows Promising Phase 2 Results for Crohn's Disease
- Clinical Trial Success: RHB-104 demonstrated a 64% improvement in efficacy in its Phase 3 study, achieving the primary endpoint of clinical remission, indicating a significant advantage in treating Crohn's disease and potentially transforming current treatment paradigms.
- New Drug Development Progress: In vitro testing of RHB-204 showed comparable Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy to RHB-104, but with lower doses of active ingredients, suggesting reduced toxicity and side effects, thereby enhancing patient adherence.
- Significant Market Opportunity: The Crohn's disease market is projected to grow from $13.6 billion in 2024 to over $19 billion by 2033, with FDA approval of RHB-204 potentially providing substantial market share and revenue opportunities for the company.
- Clear Regulatory Pathway: RHB-204 is expected to receive FDA pediatric orphan drug designation and breakthrough therapy designation, further enhancing its competitive edge and regulatory advantages, which are anticipated to yield long-term strategic benefits for the company.
See More
Cumberland Pharmaceuticals Q1 2026 Earnings Call Insights
- FDA Approval Expansion: Cumberland received FDA approval for expanded Caldolor labeling, now indicated for patients aged 3 months and older, which is expected to enhance market demand and strengthen product competitiveness.
- Strategic Transaction Progress: Cumberland has entered into an agreement with Apotex to sell its portfolio of marketed products for $100 million, which is anticipated to significantly reduce operating expenses and refocus the company on innovative product development.
- Financial Performance Overview: In Q1 2026, Cumberland's total revenue from FDA-approved brands was $9.1 million, while total operating expenses reached $12.3 million, resulting in a net loss of approximately $3.3 million, indicating challenges in profitability.
- Outlook Adjustment: Due to the impact of the strategic transaction, Cumberland is no longer targeting double-digit revenue growth for 2026, with management shifting focus towards cost reduction and advancing its product pipeline.
See More
CUMBERLAND PHARMACEUTICALS REPORTS Q1 ADJUSTED EPS OF USD -0.13
Company Overview: Cumberland Pharmaceuticals is a pharmaceutical company focused on developing and marketing innovative products for hospitals and specialty markets.
Financial Performance: The company reported a Q1 adjusted EPS of USD -0.13, indicating a loss during the quarter.
Market Position: Cumberland Pharmaceuticals aims to enhance its market presence through strategic partnerships and product development.
Future Outlook: The company is focused on expanding its product pipeline and improving financial performance in upcoming quarters.
See More
Cumberland Pharmaceuticals Reports Q1 Revenue of $9.1 Million
Company Overview: Cumberland Pharmaceuticals is a pharmaceutical company focused on developing and marketing innovative products.
Financial Performance: The company reported a revenue of USD 9.1 million for the first quarter.
See More
Cumberland Pharmaceuticals Strategic Transaction Unlocks $100 Million in Value
- Strategic Transaction Overview: Cumberland Pharmaceuticals has entered into a strategic transaction with Apotex, Canada’s largest pharmaceutical company, to acquire its portfolio of FDA-approved brands for $100 million in cash, aimed at unlocking value and sharpening focus on high-value product candidates.
- Financial Performance: In Q1 2026, Cumberland reported net revenues of $9.1 million, reflecting a 5% increase from Q1 2025, despite operating expenses reaching $12.3 million, resulting in a net loss of approximately $3.3 million, indicating challenges in expanding its product line.
- R&D Progress: Cumberland's ifetroban product has achieved breakthrough results in a Phase II clinical trial for patients with Duchenne muscular dystrophy, with the FDA granting Fast Track designation, which is expected to expedite its approval process and address unmet medical needs.
- Balance Sheet Status: As of March 31, 2026, Cumberland had total assets of $71 million, liabilities of $49.7 million, and shareholders' equity of $21.6 million, demonstrating financial stability and potential for future growth.
See More
Cumberland Pharmaceuticals Strategic Transaction Unlocks $100 Million in Value
- Strategic Transaction Announcement: Cumberland Pharmaceuticals has entered into a strategic transaction with Apotex, Canada's largest pharmaceutical company, to acquire its portfolio of FDA-approved brands for $100 million in cash, aimed at enhancing the company's focus on developing high-value product candidates to address unmet medical needs.
- Financial Performance Review: In the first quarter of 2026, Cumberland reported net revenues of $9.1 million, reflecting a 5% increase compared to the same period in 2025, indicating strong market performance following a year of double-digit growth in 2025, despite facing operating expenses totaling $12.3 million.
- R&D Pipeline Progress: Cumberland is developing ifetroban, a potent thromboxane antagonist for Duchenne muscular dystrophy, which has received Fast Track Designation from the FDA, potentially accelerating its clinical development and enhancing the company's competitive position in the biopharmaceutical sector.
- Balance Sheet Status: As of March 31, 2026, Cumberland's total assets stood at $71 million, with liabilities of $49.7 million and shareholders' equity of $21.6 million, demonstrating financial stability that supports future strategic investments and R&D initiatives.
See More
RedHill's RHB-204 Shows Promising Phase 2 Results for Crohn's Disease
- Clinical Trial Success: RHB-104 demonstrated a 64% improvement in efficacy in its Phase 3 study, achieving the primary endpoint of clinical remission, indicating a significant advantage in treating Crohn's disease and potentially transforming current treatment paradigms.
- New Drug Development Progress: In vitro testing of RHB-204 showed comparable Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy to RHB-104, but with lower doses of active ingredients, suggesting reduced toxicity and side effects, thereby enhancing patient adherence.
- Significant Market Opportunity: The Crohn's disease market is projected to grow from $13.6 billion in 2024 to over $19 billion by 2033, with FDA approval of RHB-204 potentially providing substantial market share and revenue opportunities for the company.
- Clear Regulatory Pathway: RHB-204 is expected to receive FDA pediatric orphan drug designation and breakthrough therapy designation, further enhancing its competitive edge and regulatory advantages, which are anticipated to yield long-term strategic benefits for the company.
See More
